Cargando…
A Novel Targeted RIG-I Receptor 5′Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine
The rapid mutation and spread of SARS-CoV-2 variants recently, especially through the emerging variants Omicron BA5, BF7, XBB and BQ1, necessitate the development of universal vaccines to provide broad spectrum protection against variants. For the SARS-CoV-2 universal recombinant protein vaccines, a...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220529/ https://www.ncbi.nlm.nih.gov/pubmed/37243185 http://dx.doi.org/10.3390/v15051099 |
_version_ | 1785049239587389440 |
---|---|
author | Bai, Yu An, Chaoqiang Zhang, Xuanxuan Li, Kelei Cheng, Feiran Cui, Bopei Song, Ziyang Liu, Dong Zhang, Jialu He, Qian Liu, Jianyang Mao, Qunying Liang, Zhenglun |
author_facet | Bai, Yu An, Chaoqiang Zhang, Xuanxuan Li, Kelei Cheng, Feiran Cui, Bopei Song, Ziyang Liu, Dong Zhang, Jialu He, Qian Liu, Jianyang Mao, Qunying Liang, Zhenglun |
author_sort | Bai, Yu |
collection | PubMed |
description | The rapid mutation and spread of SARS-CoV-2 variants recently, especially through the emerging variants Omicron BA5, BF7, XBB and BQ1, necessitate the development of universal vaccines to provide broad spectrum protection against variants. For the SARS-CoV-2 universal recombinant protein vaccines, an effective approach is necessary to design broad-spectrum antigens and combine them with novel adjuvants that can induce high immunogenicity. In this study, we designed a novel targeted retinoic acid-inducible gene-I (RIG-I) receptor 5′triphosphate double strain RNA (5′PPP dsRNA)-based vaccine adjuvant (named AT149) and combined it with the SARS-CoV-2 Delta and Omicron chimeric RBD-dimer recombinant protein (D-O RBD) to immunize mice. The results showed that AT149 activated the P65 NF-κB signaling pathway, which subsequently activated the interferon signal pathway by targeting the RIG-I receptor. The D-O RBD + AT149 and D-O RBD + aluminum hydroxide adjuvant (Al) + AT149 groups showed elevated levels of neutralizing antibodies against the authentic Delta variant, and Omicron subvariants, BA1, BA5, and BF7, pseudovirus BQ1.1, and XBB compared with D-O RBD + Al and D-O RBD + Al + CpG7909/Poly (I:C) groups at 14 d after the second immunization, respectively. In addition, D-O RBD + AT149 and D-O RBD + Al + AT149 groups presented higher levels of the T-cell-secreted IFN-γ immune response. Overall, we designed a novel targeted RIG-I receptor 5′PPP dsRNA-based vaccine adjuvant to significantly improve the immunogenicity and broad spectrum of the SARS-CoV-2 recombinant protein vaccine. |
format | Online Article Text |
id | pubmed-10220529 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102205292023-05-28 A Novel Targeted RIG-I Receptor 5′Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine Bai, Yu An, Chaoqiang Zhang, Xuanxuan Li, Kelei Cheng, Feiran Cui, Bopei Song, Ziyang Liu, Dong Zhang, Jialu He, Qian Liu, Jianyang Mao, Qunying Liang, Zhenglun Viruses Brief Report The rapid mutation and spread of SARS-CoV-2 variants recently, especially through the emerging variants Omicron BA5, BF7, XBB and BQ1, necessitate the development of universal vaccines to provide broad spectrum protection against variants. For the SARS-CoV-2 universal recombinant protein vaccines, an effective approach is necessary to design broad-spectrum antigens and combine them with novel adjuvants that can induce high immunogenicity. In this study, we designed a novel targeted retinoic acid-inducible gene-I (RIG-I) receptor 5′triphosphate double strain RNA (5′PPP dsRNA)-based vaccine adjuvant (named AT149) and combined it with the SARS-CoV-2 Delta and Omicron chimeric RBD-dimer recombinant protein (D-O RBD) to immunize mice. The results showed that AT149 activated the P65 NF-κB signaling pathway, which subsequently activated the interferon signal pathway by targeting the RIG-I receptor. The D-O RBD + AT149 and D-O RBD + aluminum hydroxide adjuvant (Al) + AT149 groups showed elevated levels of neutralizing antibodies against the authentic Delta variant, and Omicron subvariants, BA1, BA5, and BF7, pseudovirus BQ1.1, and XBB compared with D-O RBD + Al and D-O RBD + Al + CpG7909/Poly (I:C) groups at 14 d after the second immunization, respectively. In addition, D-O RBD + AT149 and D-O RBD + Al + AT149 groups presented higher levels of the T-cell-secreted IFN-γ immune response. Overall, we designed a novel targeted RIG-I receptor 5′PPP dsRNA-based vaccine adjuvant to significantly improve the immunogenicity and broad spectrum of the SARS-CoV-2 recombinant protein vaccine. MDPI 2023-04-29 /pmc/articles/PMC10220529/ /pubmed/37243185 http://dx.doi.org/10.3390/v15051099 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Bai, Yu An, Chaoqiang Zhang, Xuanxuan Li, Kelei Cheng, Feiran Cui, Bopei Song, Ziyang Liu, Dong Zhang, Jialu He, Qian Liu, Jianyang Mao, Qunying Liang, Zhenglun A Novel Targeted RIG-I Receptor 5′Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine |
title | A Novel Targeted RIG-I Receptor 5′Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine |
title_full | A Novel Targeted RIG-I Receptor 5′Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine |
title_fullStr | A Novel Targeted RIG-I Receptor 5′Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine |
title_full_unstemmed | A Novel Targeted RIG-I Receptor 5′Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine |
title_short | A Novel Targeted RIG-I Receptor 5′Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine |
title_sort | novel targeted rig-i receptor 5′triphosphate double strain rna-based adjuvant significantly improves the immunogenicity of the sars-cov-2 delta-omicron chimeric rbd-dimer recombinant protein vaccine |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220529/ https://www.ncbi.nlm.nih.gov/pubmed/37243185 http://dx.doi.org/10.3390/v15051099 |
work_keys_str_mv | AT baiyu anoveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT anchaoqiang anoveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT zhangxuanxuan anoveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT likelei anoveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT chengfeiran anoveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT cuibopei anoveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT songziyang anoveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT liudong anoveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT zhangjialu anoveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT heqian anoveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT liujianyang anoveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT maoqunying anoveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT liangzhenglun anoveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT baiyu noveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT anchaoqiang noveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT zhangxuanxuan noveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT likelei noveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT chengfeiran noveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT cuibopei noveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT songziyang noveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT liudong noveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT zhangjialu noveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT heqian noveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT liujianyang noveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT maoqunying noveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine AT liangzhenglun noveltargetedrigireceptor5triphosphatedoublestrainrnabasedadjuvantsignificantlyimprovestheimmunogenicityofthesarscov2deltaomicronchimericrbddimerrecombinantproteinvaccine |